118 related articles for article (PubMed ID: 35073441)
1. Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer.
Chong CY; Jalali A; Wong HL; Loft M; Wong R; Lee M; Gately L; Hong W; Shapiro J; Kosmider S; Tie J; Ananda S; Yeung JM; Ma B; Burge M; Jennens R; Tran B; Lee B; Lim L; Dean A; Nott L; Gibbs P
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e363-e368. PubMed ID: 35073441
[TBL] [Abstract][Full Text] [Related]
2. Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Jalali A; Gard G; Banks S; Dunn C; Wong HL; Wong R; Lee M; Gately L; Loft M; Shapiro JD; Kosmider S; Tie J; Ananda S; Yeung JM; Jennens R; Lee B; McKendrick J; Lim L; Khattak A; Gibbs P
Curr Probl Cancer; 2022 Apr; 46(2):100793. PubMed ID: 34565601
[TBL] [Abstract][Full Text] [Related]
3. Middle East and North Africa Registry to Characterize Rate of RAS Testing Status in Newly Diagnosed Patients with Metastatic Colorectal Cancer.
Oukkal M; Bouzid K; Bounedjar A; Alnajar A; Taleb FA; Alsharm A; Mahfouf H; Larbaoui B; Abdelaziz A; Ouamer A; Bashir L
Turk J Gastroenterol; 2023 Feb; 34(2):118-127. PubMed ID: 36445057
[TBL] [Abstract][Full Text] [Related]
4. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population.
Min ST; Roohullah A; Tognela A; Jalali A; Lee M; Wong R; Shapiro J; Burge M; Yip D; Nott L; Zimet A; Lee B; Dean A; Steel S; Wong HL; Gibbs P; Lim SH
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e56-e63. PubMed ID: 33870631
[TBL] [Abstract][Full Text] [Related]
5. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
Lièvre A; Merlin JL; Sabourin JC; Artru P; Tong S; Libert L; Audhuy F; Gicquel C; Moureau-Zabotto L; Ossendza RA; Laurent-Puig P; Ducreux M
Dig Liver Dis; 2018 May; 50(5):507-512. PubMed ID: 29396127
[TBL] [Abstract][Full Text] [Related]
6. How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?
Au L; Turner N; Wong HL; Field K; Lee B; Boadle D; Cooray P; Karikios D; Kosmider S; Lipton L; Nott L; Parente P; Tie J; Tran B; Wong R; Yip D; Shapiro J; Gibbs P
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e167-e174. PubMed ID: 28299879
[TBL] [Abstract][Full Text] [Related]
7. Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia.
Turner NH; Wong HL; Field K; Wong R; Shapiro J; Yip D; Nott L; Tie J; Kosmider S; Tran B; Desai J; McKendrick J; Zimet A; Richardson G; Iddawela M; Gibbs P
Asia Pac J Clin Oncol; 2015 Sep; 11(3):262-71. PubMed ID: 25871458
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.
Unim B; Pitini E; De Vito C; D'Andrea E; Marzuillo C; Villari P
Value Health; 2020 Jan; 23(1):114-126. PubMed ID: 31952666
[TBL] [Abstract][Full Text] [Related]
9. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
Grasselli J; Elez E; Caratù G; Matito J; Santos C; Macarulla T; Vidal J; Garcia M; Viéitez JM; Paéz D; Falcó E; Lopez Lopez C; Aranda E; Jones F; Sikri V; Nuciforo P; Fasani R; Tabernero J; Montagut C; Azuara D; Dienstmann R; Salazar R; Vivancos A
Ann Oncol; 2017 Jun; 28(6):1294-1301. PubMed ID: 28368441
[TBL] [Abstract][Full Text] [Related]
10. The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.
Lièvre A; Artru P; Guiu M; Laurent-Puig P; Merlin JL; Sabourin JC; Viguier J; Bastie A; Seronde A; Ducreux M
Eur J Cancer; 2013 Jun; 49(9):2126-33. PubMed ID: 23473612
[TBL] [Abstract][Full Text] [Related]
11. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
Allegra CJ; Rumble RB; Hamilton SR; Mangu PB; Roach N; Hantel A; Schilsky RL
J Clin Oncol; 2016 Jan; 34(2):179-85. PubMed ID: 26438111
[TBL] [Abstract][Full Text] [Related]
12. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type.
Finkelstein SD; Sayegh R; Christensen S; Swalsky PA
Cancer; 1993 Jun; 71(12):3827-38. PubMed ID: 8508351
[TBL] [Abstract][Full Text] [Related]
13. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status.
Odisio BC; Yamashita S; Huang SY; Harmoush S; Kopetz SE; Ahrar K; Shin Chun Y; Conrad C; Aloia TA; Gupta S; Hicks ME; Vauthey JN
Br J Surg; 2017 May; 104(6):760-768. PubMed ID: 28240361
[TBL] [Abstract][Full Text] [Related]
14. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
[TBL] [Abstract][Full Text] [Related]
15. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
Vidal J; Muinelo L; Dalmases A; Jones F; Edelstein D; Iglesias M; Orrillo M; Abalo A; Rodríguez C; Brozos E; Vidal Y; Candamio S; Vázquez F; Ruiz J; Guix M; Visa L; Sikri V; Albanell J; Bellosillo B; López R; Montagut C
Ann Oncol; 2017 Jun; 28(6):1325-1332. PubMed ID: 28419195
[TBL] [Abstract][Full Text] [Related]
16. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.
Wang F; Huang YS; Wu HX; Wang ZX; Jin Y; Yao YC; Chen YX; Zhao Q; Chen S; He MM; Luo HY; Qiu MZ; Wang DS; Wang FH; Xu M; Li YH; Xu RH
Gut; 2022 Jul; 71(7):1340-1349. PubMed ID: 34489309
[TBL] [Abstract][Full Text] [Related]
17. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
20. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.
Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M
Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
